WashPost: A rare deterrent to limitless drug price increases may die under Trump

As drug prices have soared, lawmakers and patient advocates have pushed the federal government to deploy for the first time a powerful deterrent: a legal provision that allows it to suspend a drugmaker’s patent and license someone else to produce the drug.

Now, responding to industry alarm over those demands, the Trump administration is proposing to strictly limit the little-known power.

The move by the Department of Commerce is supported by drug manufacturers and research universities but could undermine Trump’s populist message of attacking drug prices. He declared in his first news conference after his inauguration that drug companies are “getting away with murder” and has called lowering prices one of his “greatest priorities.’’
Critics say the Commerce Department move is a triumph for industry.

“If tough talk and tweets could stop price gouging, consumers could celebrate,’’ said Rep. Lloyd Doggett (D-Tex.), who said the administration is being swayed by drug company influence.

Read the full story here.

Thank you, for the encouragement and support, especially throughout these recent weeks. The low turnout does signal how much work remains to ensure Democratic victories in the General Election in November.

There are no unimportant elections and no unimportant races. From the courthouse to the statehouse to the Congress, I will be working for Democratic victories.

Make A Donation

We couldn’t spread our message of equality and opportunity for all as effectively without your financial support.
Contribute to Lloyd’s efforts today to help him work for us to move our country forward and ensure victory up and down the 2022 ballot.